Medable alternatives for teams running DCTs outside top 50 pharma

Medable makes sense if you're top 50 pharma running a late-stage DCT. Outside that, the pricing and implementation model rarely fits. WeGuide gives smaller teams the same DCT building blocks, eCOA, eConsent, wearables, and a whitelabel participant app, with configuration typically taking two to four weeks.

Organise a demo See the full comparison

No pressure, no hard sell. A 30-minute walkthrough with a research colleague who's built platforms like yours.

Where WeGuide differs

Mid market accessibility
Broader use cases beyond DCTs
Deploy in weeks, not enterprise cycles

Used by leading research and medical institutes.

Why research teams look for a Medable alternative

The short version

Medable's product and commercial model were both designed around a specific customer: top 50 pharma sponsors running decentralised Phase II to IV trials. The eCOA depth, the eConsent workflows, the patient facing app suite, and the FDA submission track record all reflect that focus. For that customer, the fit is real.

See the full comparison

Why teams look elsewhere

For everyone else, the gap shows up quickly. Academic medical centres don't have Medable-scale implementation budgets. Mid-market CROs can't justify enterprise pricing for a 200-participant study. Investigator-led research teams don't have the programme management capacity to run a Medable engagement. And use cases outside DCTs, like registries, population health, employee wellbeing, and citizen science, sit entirely outside Medable's product scope.

Key differences between WeGuide and Medable

For teams that need DCT architecture but don't fit Medable's enterprise profile, here's what changes when you move to WeGuide.

Mid market accessibility

While enterprise platforms are built for massive pharma budgets, WeGuide is designed for the agility of academic centers and mid-market CROs. Our project-based pricing scales to your study’s actual complexity, with every essential module, from eConsent to wearables, included in the core license. Configuration alongside your team typically takes two to four weeks, so you get enterprise scale without the enterprise price tag.

Broader use cases beyond DCTs

WeGuide is more than just a DCT platform; it is a versatile engine for a vast range of research. From population health studies like GenV to multilingual community health initiatives and wearable integrations, our scope covers the full spectrum of modern data collection. Whether you are running citizen science, employee wellbeing programmes, or paediatric cardiac monitoring, consolidating your diverse research needs onto one platform radically improves your total operational efficiency.

Deploy in weeks, not enterprise cycles

Don't let rigid implementation timelines stall your research. Our intuitive no code programme builder allows your research team to configure and launch studies directly, removing the need for a dedicated technical implementation team or third-party developers. For mid market sponsors, this autonomy is a critical competitive advantage it is the difference between getting a study into the field this quarter or waiting until next year. Take control of your timeline and See the Form Builder →

Compare

Full comparison: WeGuide vs Medable

REDCap

Feature

Request a Demo

Primary use case

Patient engagement and clinical trial platform for mid market sponsors, academic research, registries, DCTs

Decentralised trial platform for top 50 pharma sponsors

Target customer

Mid market sponsors, academic research, CROs, registries, digital health programmes

Top 50 pharma sponsors, enterprise CROs, large biotech

Typical deployment time

Typically two to four weeks of configuration

Enterprise implementation cycles

Pricing model

Project based, all modules included, scales to study complexity

Enterprise custom quoted, typically six figure minimums

eCOA and ePRO

Native with a validated instrument library

Deep eCOA library, FDA submission history

eConsent

Built in with regulatory version control

Whitelabel mobile app

Yes, fully branded under your organisation

Medable branded participant experience

Native wearable integration

Native Garmin, Apple Health, Health Connect, and Fitbit Air

Supported through partner integrations

Telehealth

Built in video visit and virtual site features

Built in virtual site capabilities

Patient registry

Built in longitudinal registry (GenV: about 124,000 people)

Not a native use case

Employee wellbeing and population health

Built in

Outside the platform's scope

No code programme builder

Yes, research teams configure studies directly

Enterprise implementation team required

Regulatory certification

TGA Class I medical device, ISO 27001, 21 CFR Part 11, HIPAA, GDPR

21 CFR Part 11, extensive FDA submission history

Australian data residency

Yes

Not native

Knowledge and educational content

Case studies, platform documentation, blog

Industry leading knowledge centre

REDCap

Top alternatives to Medable in 2026

Here's the shortlist of decentralised trial platforms most teams evaluate when they're looking at alternatives to Medable.

Alternative #1

Where WeGuide goes further

For teams that want the participant side of a study in one platform, here's what changes when you move to WeGuide.

Mid market accessibility

Medable's pricing and implementation model are built around enterprise pharma budgets and dedicated programme teams. For academic medical centres, mid market CROs, investigator led studies, and digital health programmes, that fit isn't there. WeGuide is project based and scales to the study's actual complexity, with every module (eCOA, eConsent, registry, telehealth, wearables, analytics) included in the core licence. Configuration alongside your team typically takes two to four weeks.

Broader use cases beyond DCTs

Medable's product scope is decentralised trials. WeGuide covers a wider set of research use cases: patient registries (GenV: about 124,000 people), population health, employee wellbeing, citizen science, paediatric cardiac monitoring (Beat2Beat), and multilingual community health studies (INHERIT). If your programme includes more than traditional DCT trials, running everything on one platform changes the total cost and operational picture.

Deploy in weeks, not enterprise cycles

The no code programme builder lets research teams configure studies directly without waiting for a dedicated implementation team. For mid market sponsors, that's the difference between a study that launches this quarter and one that launches next year. See the Form Builder →

Whitelabel mobile apps under your brand

Medable's participant facing experience sits under the Medable product brand. WeGuide ships native iOS and Android apps fully branded under your organisation's name and identity. For registries, patient engagement programmes, and sponsor branded studies, this changes how the study feels to the participant.

Native wearable integration

Garmin, Apple Health, Health Connect and Fitbit Air integrations are built into WeGuide directly. Medable supports wearables through partner integrations, which works but adds a layer of procurement and integration complexity. For studies where sensor data is central to the protocol, native integration matters. See supported wearable devices →

Australian data residency and TGA registration

WeGuide is TGA registered Class I medical device software with Australian data residency. For APAC research, especially Australian investigator led studies and sponsor programmes, that's a meaningful differentiator that global platforms can't match without a local hosting partner.

Built for regulated research

Every WeGuide study runs on our managed infrastructure. Your IT team doesn't patch servers, manage backups, or run disaster recovery drills.

TGA Registered

Registered Class I medical device software with the Therapeutic Goods Administration.

ISO 27001

Certified information security management covering access, audit, and incident response.

Data Hosted in Australia

Participant data is hosted in Australian data centres with sovereign data controls.

GDPR Compliant

Supports GDPR, HIPAA and 21 CFR Part 11 requirements for multi-country and US-based studies.

Biometric Security

Participant access protected by PIN code and biometric authentication on device.

256-bit AES Encryption

All data encrypted at rest and in transit with automated backups and disaster recovery.

Where Medable excels

Deep pharma sponsor relationships. Medable has been running decentralised trials for top-50 pharma sponsors for years. That track record and those relationships create trust at the enterprise level that newer platforms have to earn. If you're a pharma sponsor whose therapeutic area team has already worked with Medable, there's real value in that continuity.

Comprehensive eCOA, eConsent, and patient-facing app suite. Medable has invested heavily in the decentralised trial stack. The eCOA library is deep, the eConsent workflows are regulatory mature, and the patient-facing app experience is polished. For enterprise DCTs, this is a capable platform.

Strong FDA submission experience. Medable has a multi-year track record of FDA-facing submissions with data sourced from its platform. That regulatory maturity matters for sponsors running late stage trials with direct FDA interaction.

Industry leading knowledge centre. Honestly, Medable's knowledge centre is one of the best educational resources in the DCT space. We use it as a reference point ourselves. If you're evaluating DCT concepts and vendor-agnostic best practices, it's a genuine asset to the industry.

If your study is a top 50 pharma late stage decentralised trial with enterprise budget and an experienced programme team, Medable is a defensible choice. We'd rather say that honestly than oversell what WeGuide does.

WeGuide and Medable can coexist

‍

If your enterprise pharma portfolio already runs Medable for late stage decentralised trials, you don't have to rip that out to use WeGuide for your mid-market studies, registries, or engagement programmes. Our Integration Engine connects through APIs, so teams can run hybrid portfolios where each platform covers the studies it's best suited to.

How the switch works

For teams that are ready to move beyond Medable for specific studies or run WeGuide alongside it, here's how onboarding typically plays out.

Discovery Call

A 30-minute conversation with one of our research delivery team. We look at your protocol, your current setup, and what's blocking you. No sales pitch.

Study Configuration

Our team works alongside yours to configure the study in WeGuide. Typical timeline: two to four weeks.

Participant Onboarding

The whitelabel app goes live. Your research coordinators invite participants, who download the app under your organisation's brand. eCOA instruments, consent flows, and engagement templates are ready.

Ongoing Support

You get a named research delivery contact, not a ticketing queue. We stay involved for the life of the study.

Case studies: research teams that run DCTs at mid market pace

BRACE Trial (Murdoch Children's Research Institute)

An international randomised controlled trial studying whether the BCG vaccine could reduce COVID-19 symptom severity in healthcare workers, run across several countries with thousands of participants. It was a hybrid trial, with in person vaccination and blood collection. The study needed a digital participant layer alongside its site visits, without an enterprise implementation timeline.

GenV (Generation Victoria)

A population health study following roughly 124,000 Victorians (about 50,000 children from birth and 74,000 parents). Longitudinal registry work at this scale sits outside Medable's DCT focus. The whitelabel family-facing app is the reason retention has held across multiple years.

FSHD Global

A longitudinal patient registry for facioscapulohumeral muscular dystrophy, combining patient reported outcomes with wearable integration. Participants report from home on their own phones, devices sync in the background, and the registry keeps a continuous picture of a rare disease over time instead of a snapshot at each clinic visit.

Helping researchers transform ideas into discoveries.

Hear what our clients have to say!

"GenV trusted WeGuide to run a multi-year population health study with roughly 124,000 Victorians, about 50,000 children and 74,000 parents. Longitudinal engagement at this scale requires push notifications, multi-modal data capture, and a whitelabel app that families will keep on their phones for years.""

Susan Clifford

Senior Research Officer

“The main benefit of WeGuide is its convenience. I can’t imagine how we would follow thousands of participants and collect their data without WeGuide!”

Kaya Gardiner

Trial Project Manager

"WeGuide has transformed how we manage our patient registry. The ease of digital screening and obtaining eConsent has significantly improved our workflow."

Emma Weatherley

Managing Director

"The WeGuide trial offers staff a practical tool for recording daily COVID-19 symptoms and temperatures. For those in high-risk areas, daily reminders and alerts provide peace of mind and reassurance about their health."

Kate Cranwell

Manager

"It’s obvious that WeGuide is committed to develop technology that benefits people in the community. WeGuide has been a great partner in achieving this goal within Western Health."

Paul Eleftheriou

Chief Medical Officer

Questions

Straight answers on how WeGuide compares to Medable, what migration looks like, and when Medable is the right call.

Is WeGuide a full replacement for Medable?

For decentralised trials run by top 50 pharma sponsors, Medable's enterprise depth and FDA submission track record are genuinely hard to match, and we'll tell you that honestly. WeGuide is the right choice when you're a mid market sponsor, academic CRO, research institution, or digital health programme that needs the same DCT architecture (eCOA, eConsent, telehealth, wearables, whitelabel app) at a pace and price point that matches your research scope. Many of the teams we work with evaluated Medable first, concluded it wasn't the right fit for their mid-market study, and chose WeGuide for the same protocol.

Does WeGuide have an eCOA product like Medable?

Yes. WeGuide's eCOA is integrated into the Form Builder with a library of validated instruments, and it runs inside the same whitelabel app participants use for the rest of the study. The main architectural difference is that WeGuide's eCOA is part of a single integrated participant experience rather than sitting alongside a separate eConsent or engagement module. For mid market DCTs, that integration is often more valuable than specialist depth.

Does WeGuide support hybrid and decentralised trials?

Yes. Decentralised trial architecture is a core WeGuide use case. Telehealth, eConsent, remote monitoring, eCOA, whitelabel participant apps, wearables, and engagement are all built in. The BRACE Trial shows how this works in a hybrid design: an international trial with thousands of participants across several countries, where the digital layer ran alongside in person vaccination and blood collection.

How does WeGuide's knowledge centre compare to Medable's?

Medable's knowledge centre is genuinely excellent, and we'll happily recommend it as a reference for DCT concepts. WeGuide's strength is different. We publish case studies, platform documentation, and a research focused blog, and our real investment goes into working alongside research teams during study setup and delivery. The knowledge centre comparison is probably the one area where Medable has a clear edge, and we're comfortable saying that.

How do Medable and WeGuide compare on FDA facing submissions?

Both platforms support 21 CFR Part 11 requirements. Medable has a longer FDA submission track record because of its pharma sponsor base. WeGuide adds TGA Class I medical device certification, ISO 27001, HIPAA, GDPR, and Australian data residency, which matters for APAC and globally distributed studies. For mid-market FDA facing work, WeGuide's compliance posture is appropriate. For enterprise late stage Phase III submissions under significant FDA scrutiny, a longer sponsor precedent may weigh in Medable's favour.

How does pricing compare?

Medable is enterprise custom quoted, typically with six figure minimums for a single study. WeGuide is project based and scales to the study's actual complexity, with every module included in the core licence. For mid market sponsors, academic research, and investigator-led studies, WeGuide is typically significantly less expensive, and the implementation cost is lower because you don't need a dedicated enterprise programme team.

More comparisons